Food and Drug Administration (FDA)
NEWS
This morning, Mylan announced the launch of its new generic offering, dimethyl fumarate delayed-release capsules for the treatment of relapsing forms of multiple sclerosis.
Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
The U.S. Food and Drug Administration approved Genentech’s Enspryng (satralizumab-mwge) as a subcutaneous treatment for adults with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
The U.S. Food and Drug Administration (FDA) approved another therapy for Duchenne muscular dystrophy (DMD), this time NS Pharma’s Viltepso (viltolarsen).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
JOBS
IN THE PRESS